Physician

Aastha Parsa, MD

According to 2025 Medicare claims, Aastha Parsa, MD (NPI: 1588871594) practices nephrology in the Cape Coral-Fort Myers, FL market, with the plurality of this provider's patient population coming from Lee, FL. This provider's primary affiliated billing organization is ASSOCIATES IN NEPHROLOGY BUTCHER & DEVACAANTHAN MD PA (NPI: 1437100146; TIN: 592412674) and primary practice location at 33908-3692.

Parsa's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 312 traditional Medicare patients, billed 730 HCPCS/CPT codes, and received $74,545 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,400 prescription claims across 314 beneficiaries totaling $269,193 in drug costs, led by Jardiance (Empagliflozin). DME data shows 53 claims. Open Payments data shows 7 records totaling $223. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $113,984 and ending at $74,545. Concurrently, Part D prescription costs have risen steadily, from $28,568 to $269,193. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	544	1,408	$113,984
2016	486	1,261	$112,691
2017	515	1,353	$125,051
2018	496	1,455	$134,171
2019	207	725	$60,165
2020	298	908	$94,495
2021	523	1,157	$133,952
2022	512	997	$96,187
2023	307	676	$66,283
2024	312	730	$74,545

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	89	334	$28,568
2016	100	513	$33,022
2017	103	605	$68,272
2018	116	527	$25,431
2019	145	378	$49,832
2020	186	904	$120,814
2021	282	1,135	$167,410
2022	287	1,255	$136,766
2023	296	1,243	$199,950
2024	314	1,400	$269,193

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	60	$2,481
2021	N/R	43	$1,719
2022	N/R	63	$1,461
2023	N/R	68	$1,274
2024	N/R	53	$864

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	20	20	$122
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	202	336	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	35	64	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	34	35	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	25	26	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	53	4,650	$87,417
Farxiga	Dapagliflozin Propanediol	59	4,725	$84,415
Renvela	Sevelamer Carbonate	16	720	$25,935
Sevelamer Carbonate	Sevelamer Carbonate	27	1,865	$5,403
Calcitriol	Calcitriol	256	22,186	$3,524

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	11	$301
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	16	$231
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$169
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$223	Intera Oncology, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aastha Parsa, MD?

Tedicare shows public-source Medicare data for Aastha Parsa, MD (NPI 1588871594), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aastha Parsa, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aastha Parsa, MD?

Aastha Parsa, MD is linked to ASSOCIATES IN NEPHROLOGY BUTCHER & DEVACAANTHAN MD PA (billing NPI 1437100146) in the available physician profile data.

Does Aastha Parsa, MD have Open Payments data?

Aastha Parsa, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.